Atrial Fibrillation Resource

Atrial fibrillation (Afib) currently affects more than four million Europeans, and prevalence increases with age (ref. 1-3). Optimizing Afib management in an aging population is becoming an important healthcare issue. Afib increases the risk of stroke, reduces quality of life both directly and indirectly, and is responsible for significant healthcare costs (ref. 4-11).


This site has been established as an educational resource for all healthcare professionals involved in the management of patients with Afib, and provides a range of resources focusing on the latest debates and developments in the field.



Publication Scan

picto-files 21-2009
Singh SM, D'Avila A, Kim SJ, Houghtaling C, Dukkipati SR, Reddy VY.
Intraprocedural Use of Ibutilide to Organize and Guide Ablation of Complex Fractionated Atrial Electrograms: Preliminary Assessment of a Modified Step-Wise Approach to Ablation of Persistent Atrial Fibrillation.

picto-files 12-05-2009
Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN.
The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS Score 1.

picto-files 07-12-2009
Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E.
Up-dated Worldwide Survey on the Methods, Efficacy and Safety of Catheter Ablation for Human Atrial Fibrillation.




©Johnson & Johnson Medical NV/SA, 2010. Last update on:27 Mar 2013 This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its contents. This section of the website is intended for visitors from the European Economic Area (EEA), excluding France. The EEA includes the 25 EU member states and Norway, Iceland, and Liechtenstein. Capitalized product names are trademarks of Biosense Webster.